Your browser doesn't support javascript.
loading
Iron chelation, quo vadis?
Nick, Hanspeter.
Affiliation
  • Nick H; Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland. hanspeter.nick@novartis.com
Curr Opin Chem Biol ; 11(4): 419-23, 2007 Aug.
Article de En | MEDLINE | ID: mdl-17644021
Orally bioavailable chelators for transfusional iron overload have been sought since the introduction of deferoxamine (Desferal) in 1962. Despite tremendous efforts, to date, only deferiprone (Ferriprox) and deferasirox (Exjade) have successfully reached the market, reflecting the difficulty to combine oral activity and safety. Owing to the risk of failure, few new oral chelators can be expected in the future for the treatment of transfusional iron overload. As iron is involved in many disease processes, deferiprone and deferasirox have been proposed to be potentially useful in a variety of indications not characterized by general iron overload. Although it may be possible to obtain clinical benefit from current compounds, more selective chelators tailored to the particular target are needed for successful intervention in these indications.
Sujet(s)
Recherche sur Google
Collection: 01-internacional Base de données: MEDLINE Sujet principal: Agents chélateurs du fer Limites: Humans Langue: En Journal: Curr Opin Chem Biol Sujet du journal: BIOQUIMICA Année: 2007 Type de document: Article Pays d'affiliation: Suisse Pays de publication: Royaume-Uni
Recherche sur Google
Collection: 01-internacional Base de données: MEDLINE Sujet principal: Agents chélateurs du fer Limites: Humans Langue: En Journal: Curr Opin Chem Biol Sujet du journal: BIOQUIMICA Année: 2007 Type de document: Article Pays d'affiliation: Suisse Pays de publication: Royaume-Uni